MarketPromegestone
Company Profile

Promegestone

Promegestone, sold under the brand name Surgestone, is a progestin medication which is used in menopausal hormone therapy and in the treatment of gynecological disorders. It is taken by mouth.

Medical uses
Promegestone is used in menopausal hormone therapy and in the treatment of gynecological conditions caused by luteal insufficiency, including premenopausal disorders, dysmenorrhea and other menstrual disorders, and premenstrual syndrome. Promegestone tablets have a contraceptive effect and are used as a form of progestogen-only birth control, although it is not specifically licensed as such. ==Side effects==
Side effects
Side effects of promegestone include menstrual irregularities among others. It has no androgenic side effects. ==Pharmacology==
Pharmacology
Pharmacodynamics (21(S)-hydroxyl-promegestone), the major active metabolite of promegestone. Promegestone is a progestogen, or an agonist of the progesterone receptor. It has about 200% of the affinity of progesterone for the PR. In addition, promegestone has been found to possess some neurosteroid activity by acting as a non-competitive antagonist of the nicotinic acetylcholine receptor, similarly to progesterone. Pharmacokinetics Following oral administration, peak serum levels of promegestone are reached after 1 to 2 hours. The metabolism of promegestone is mainly via hydroxylation at the C21 position and at other positions. The medication is stereoselectively metabolized into trimegestone, the 21(S)-hydroxy metabolite, which is the main compound found in plasma; it circulates at levels approximately twice those of promegestone itself. A second metabolite, 21(R)-hydroxypromegestone, circulates at far lower concentrations ( ratio for the (S)- and (R)-isomers of about 21). The elimination half-life of trimegestone is 13.8 to 15.6 hours. Promegestone, trimegestone, and 21(R)-hydroxypromegestone are not excreted in urine, while 3% of a dose is recovered as the glucuronide and/or sulfate conjugate of trimegestone and 1% of a dose is recovered as the glucuronide and/or sulfate conjugate of 21(R)-hydroxypromegestone. ==Chemistry==
Chemistry
Promegestone, also known as 17α,21-dimethyl-δ9-19-norprogesterone or as 17α,21-dimethyl-19-norpregna-4,9-diene-3,20-dione, is a synthetic norpregnane steroid and a derivative of progesterone. It is specifically a combined derivative of 17α-methylprogesterone and 19-norprogesterone, or of 17α-methyl-19-norprogesterone. Related derivatives of 17α-methyl-19-norprogesterone include demegestone and trimegestone. ==History==
History
Promegestone was first described in the literature in 1973 and was introduced for medical use in France in 1983. It was developed by Roussel Uclaf in France. ==Society and culture==
Society and culture
Generic names Promegestone is the generic name of the drug and its , while promégestone is its . It is also known by its developmental code name R-5020 or RU-5020. Brand names Promegestone is marketed exclusively under the brand name Surgestone. Availability Promegestone is or has been marketed in France, Portugal, Tunisia, and Argentina. == References ==
tickerdossier.comtickerdossier.substack.com